Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Adjuvant gemcitabine (GEM) versus gemcitabine plus capecitabine (GEMCAP) in resected pancreatic adenocarcinoma: A retrospective analysis.
Authors
Sora Kang
Asan Medical Center, Seoul, Seoul, South Korea
Sora Kang , Changhoon Yoo , So Heun Lee , Heung-Moon Chang , Jae Ho Jeong , Kyu-Pyo Kim , Baek-Yeol Ryoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.547
Abstract #
547
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A randomized, multi-center phase III trial of adjuvant chemotherapy with gemcitabine and capecitabine (GemCap) compared to capecitabine (Cap) alone in curatively resected biliary tract cancer (BilGemCap Study): KCSG HB20-14.
First Author: Joon Oh Park
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world treatments and outcomes of resected biliary tract cancers in British Columbia, Canada.
First Author: Mélina Boutin
Poster
2020 ASCO Virtual Scientific Program
TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).
First Author: Gayathri Anandappa
Poster
2019 Gastrointestinal Cancers Symposium
Adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunostaining in curative resected pancreatic adenocarcinoma: A biomaker stratified trial.
First Author: Dong Woo Shin